Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
crispr
3
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
3
×
biotech
crispr-cas9
editas medicine
national
advaxis
aimmune therapeutics
alder biopharmaceuticals
alexander hardy
alphabet
andrew oxtoby
babies
boulder/denver blog main
boulder/denver top stories
breakup
bridge bio pharma
broad institute of harvard and mit
brook byers
cancer
ceo
charles chu
clinical hold
clinical study
combination
commissioner
congress
crispr cas14
crispr therapeutics
deals
decheng capital
delisting
democrats
departure
What
cas
3
×
crispr
big
bio
medicine
today
available
based
biosciences
bosley's
bosley’s
bridge
bucks
cancer
cells
ceo
cheaper
crime
defect
departure
develop
diagnostics
drive
editas
edited
editing
exit
expects
faster
fears
flag
gene
genetic
guardian
guiding
human
katrine
known
lab
malfunction
Language
unset
Current search:
cas
×
crispr
×
" san francisco top stories "
×
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells